Cella David, Hughes Chanita, Peterman Amy, Chang Chih-Hung, Peshkin Beth N, Schwartz Marc D, Wenzel Lari, Lemke Amy, Marcus Alfred C, Lerman Caryn
Center on Outcomes Research and Education, Evanston Northwestern Healthcare, Illinois 60201, USA.
Health Psychol. 2002 Nov;21(6):564-72.
The Multidimensional Impact of Cancer Risk Assessment (MICRA) is a new tool to measure the specific impact of result disclosure after genetic testing. The authors compared its performance with that of questionnaires measuring general and cancer-specific distress. Participants (158 women) responded 1 month after they received genetic test results. The women were divided into 4 standard clinical test result groups: BRCA1/2 positive, BRCA1/2 negative, panel negative, and true negative. Factor analysis supported the formation of 3 subscales: Distress (6 items, alpha = .86), Uncertainty (9 items, alpha = .77), and Positive Experiences (4 items, alpha = .75). All 3 MICRA subscales differentiated participants who were BRCA1/2 positive from the other 3 groups. MICRA thus helps identify subgroups of vulnerable genetic testing participants.
癌症风险评估的多维影响（MICRA）是一种用于衡量基因检测结果披露的具体影响的新工具。作者将其性能与测量一般和癌症特异性困扰的问卷进行了比较。参与者（158名女性）在收到基因检测结果1个月后做出回应。这些女性被分为4个标准临床检测结果组：BRCA1/2阳性、BRCA1/2阴性、基因检测板阴性和真阴性。因子分析支持了3个分量表的形成：困扰（6个项目，α = 0.86）、不确定性（9个项目，α = 0.77）和积极体验（4个项目，α = 0.75）。所有3个MICRA分量表都区分了BRCA1/2阳性的参与者与其他3组。因此，MICRA有助于识别基因检测参与者中的脆弱亚组。
